药械指南

订阅

MedSci主页 / 所有栏目 / 药械指南

2021 CPIC指南：CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗

2021-01-02 临床药物基因组学实施联盟 Clin Pharmacol Ther . 2021 Jan 2.

阿片类药物

2021年1月，临床药物基因组学实施联盟(CPIC)发布了CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗指南。阿片类药物治疗主要用于治疗急慢性疼痛，一些阿片类药物（可待因。曲马多、羟考

中文标题：

2021 CPIC指南：CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗

英文标题：

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy

发布机构：

临床药物基因组学实施联盟

发布日期：

2021-01-02

简要介绍：

2021年1月，临床药物基因组学实施联盟(CPIC)发布了CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗指南。阿片类药物治疗主要用于治疗急慢性疼痛，一些阿片类药物（可待因。曲马多、羟考酮和美沙酮）在一定程度上被 CYP2D6代谢，其他与阿片类药物临床效应或不良事件相关的基因包括OPRM1 (μ受体)和COMT (儿茶酚-O-甲基转移酶)。本文主要基于基因型结果处方可待因和曲马多物提供建议。

 

相关资料下载：
[AttachmentFileName(sort=1, fileName=2021 CPIC指南：CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗.pdf)] GetToolGuiderByIdResponse(projectId=1, id=151aa1c002066ed9, title=2021 CPIC指南：CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗, enTitle=Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy, guiderFrom=Clin Pharmacol Ther . 2021 Jan 2., authorId=0, author=, summary=2021年1月，临床药物基因组学实施联盟(CPIC)发布了CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗指南。阿片类药物治疗主要用于治疗急慢性疼痛，一些阿片类药物（可待因。曲马多、羟考, cover=https://img.medsci.cn/202138/1615137774454_2020535.jpg, journalId=0, articlesId=null, associationId=1236, associationName=临床药物基因组学实施联盟, associationIntro=, copyright=0, guiderPublishedTime=Sat Jan 02 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<div class="one_info2" style="color: #373737;"> <div id="all_content"> <div class="editor_mirror editor_mirror_del"> <p>2021年1月，临床药物基因组学实施联盟(CPIC)发布了CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗指南。阿片类药物治疗主要用于治疗急慢性疼痛，一些阿片类药物（可待因。曲马多、羟考酮和美沙酮）在一定程度上被 CYP2D6代谢，其他与阿片类药物临床效应或不良事件相关的基因包括OPRM1 (&mu;受体)和COMT (儿茶酚-O-甲基转移酶)。本文主要基于基因型结果处方可待因和曲马多物提供建议。</p> </div> </div> </div> <div class="box_info" style="color: #373737;">&nbsp;</div>, tagList=[TagDto(tagId=9680, tagName=阿片类药物)], categoryList=[CategoryDto(categoryId=11, categoryName=药械, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=9680, guiderKeyword=阿片类药物, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=指南, guiderLanguage=1, guiderRegion=4, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=5362, appHits=55, showAppHits=0, pcHits=1062, showPcHits=5307, likes=1, shares=4, comments=10, approvalStatus=1, publishedTime=Mon Mar 08 01:49:10 CST 2021, publishedTimeString=2021-01-02, pcVisible=1, appVisible=1, editorId=2020535, editor=qiushida2, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=qiushida2, createdTime=Mon Mar 08 01:23:09 CST 2021, updatedBy=2020535, updatedName=qiushida2, updatedTime=Sat Jan 06 20:13:04 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 CPIC指南：CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗.pdf)])
2021 CPIC指南：CYP2D6, OPRM1和COMT基因型和选择阿片类药物治疗.pdf
下载请点击：
评论区 (9)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1228362, encodeId=2a28122836276, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7e6447080, createdName=ms6000000659983853, createdTime=Fri Jun 24 09:04:47 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186598, encodeId=903e118659859, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f5c3062595, createdName=264786325, createdTime=Thu Jan 20 21:25:31 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182121, encodeId=0cd3118212188, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c881519032, createdName=haopot, createdTime=Sat Jan 08 09:10:20 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073554, encodeId=c33f10e35544d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Nov 24 16:01:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003435, encodeId=e1961003435d6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c79d5558936, createdName=ms7000001330389982, createdTime=Wed Jul 28 21:09:27 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2022-06-24 ms6000000659983853

    学习了

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1228362, encodeId=2a28122836276, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7e6447080, createdName=ms6000000659983853, createdTime=Fri Jun 24 09:04:47 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186598, encodeId=903e118659859, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f5c3062595, createdName=264786325, createdTime=Thu Jan 20 21:25:31 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182121, encodeId=0cd3118212188, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c881519032, createdName=haopot, createdTime=Sat Jan 08 09:10:20 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073554, encodeId=c33f10e35544d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Nov 24 16:01:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003435, encodeId=e1961003435d6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c79d5558936, createdName=ms7000001330389982, createdTime=Wed Jul 28 21:09:27 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2022-01-20 264786325

    学习

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1228362, encodeId=2a28122836276, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7e6447080, createdName=ms6000000659983853, createdTime=Fri Jun 24 09:04:47 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186598, encodeId=903e118659859, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f5c3062595, createdName=264786325, createdTime=Thu Jan 20 21:25:31 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182121, encodeId=0cd3118212188, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c881519032, createdName=haopot, createdTime=Sat Jan 08 09:10:20 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073554, encodeId=c33f10e35544d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Nov 24 16:01:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003435, encodeId=e1961003435d6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c79d5558936, createdName=ms7000001330389982, createdTime=Wed Jul 28 21:09:27 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2022-01-08 haopot

    学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1228362, encodeId=2a28122836276, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7e6447080, createdName=ms6000000659983853, createdTime=Fri Jun 24 09:04:47 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186598, encodeId=903e118659859, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f5c3062595, createdName=264786325, createdTime=Thu Jan 20 21:25:31 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182121, encodeId=0cd3118212188, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c881519032, createdName=haopot, createdTime=Sat Jan 08 09:10:20 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073554, encodeId=c33f10e35544d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Nov 24 16:01:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003435, encodeId=e1961003435d6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c79d5558936, createdName=ms7000001330389982, createdTime=Wed Jul 28 21:09:27 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-11-24 ms2000001530004019

    学习啦

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1228362, encodeId=2a28122836276, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=dd7e6447080, createdName=ms6000000659983853, createdTime=Fri Jun 24 09:04:47 CST 2022, time=2022-06-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1186598, encodeId=903e118659859, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6f5c3062595, createdName=264786325, createdTime=Thu Jan 20 21:25:31 CST 2022, time=2022-01-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1182121, encodeId=0cd3118212188, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c881519032, createdName=haopot, createdTime=Sat Jan 08 09:10:20 CST 2022, time=2022-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1073554, encodeId=c33f10e35544d, content=学习啦, beContent=null, objectType=guider, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=22075450427, createdName=ms2000001530004019, createdTime=Wed Nov 24 16:01:22 CST 2021, time=2021-11-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1003435, encodeId=e1961003435d6, content=学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c79d5558936, createdName=ms7000001330389982, createdTime=Wed Jul 28 21:09:27 CST 2021, time=2021-07-28, status=1, ipAttribution=)]
    2021-07-28 ms7000001330389982

    学习了

    0

相关指南

2020 CAEP立场声明：阿片类药物使用障碍患者的急诊管理

加拿大急诊医师协会(CAEP,Canadian Association of Emergency Physicians) · 2020-11-20

关于预防成年手术患者阿片类药物相关伤害的国际多学科共识声明 2020

暂未更新 · 2020-10-06

2020 ASAM国家实践指南：阿片类药物使用障碍的治疗

暂未更新 · 2020-04-20

2020 CCSHM指南：阿片类使用障碍

加拿大老年人心理健康联盟(CCSHM,Canadian Coalition for Seniors’ Mental Health) · 2020-03-30

2019 多学科专家共识：普通牙科手术阿片类药物指南

国外口腔科相关专家组（统称） · 2019-10-11

2019 SPA建议：儿童围手术期阿片类药物的应用

儿科麻醉学会(SPA,Society for Pediatric Anesthesia) · 2019-03-31

拓展阅读

2014 新西兰实践指南：阿片类药物替代治疗

新西兰卫生部(New Zealand Ministry of Health) · 2014-04-11

2014 WHO阿片类药物应用过量的社区管理

世界卫生组织(WHO,The World Health Organization) · 2014-10-01

JAMA：CDC 2016 阿片类药物镇痛使用指南

美国疾病控制与预防中心(CDC,Centers for Disease Control and Prevention) · 2016-03-21

2016 香港指南：阿片类药物治疗慢性非癌痛

香港医学相关专家组（统称） · 2016-10-05

【精华指南】驾驭癌性疼痛，权衡阿片药物剂量，医生无需纠结

暂未更新 · 2017-03-09

2016 CPSBC阿片类药物滥用指南：美沙酮和丁丙诺啡

不列颠哥伦比亚内外科医师学会(CPSBC,College of Physicians and Surgeons of British Columbia) · 2016-07-01